RD&C developed a novel systemic analysis concept for impurity profiling in pharmaceutical drug process development and impurity related deviation management at development stage or in routine drug manufacturing.
Yogeshwar G. Bachhav, PhD, is joining RD&C to strengthen our expertise in the field of formulation development for poorly soluble drugs for oral, parenteral and topical/transdermal applications.
RD&C succeeded in establishing a consortium of 8 partners involving research institutes, universities and pharmaceutical industry to initiate the establishment of an impurity database! The kick-off meeting took place on July 14th, 2015 in Barcelona/Spain.
First solid phase degradation experiments are being performed at research two institutes specializing in solid phase chemisty i.e. mechanochemistry and heterogeneous catalysis: RWTH Aachen, Institut für Organische Chemie, Prof. Dr. Carsten Bolm and at the LIKAT, Leibniz-Institut für Katalyse, Rostock, Germany
This accredited chartered engineer status warrants fitness for combining a broad technical background with an objective view, directed towards protecting the clients’ interests and ensuring superior performance at the lowest commensurate cost. Chartered engineer status ensures quality, employability and professional recognition.
Highly cost efficient Environmental Risk Assessments (ERAs) at a minimum of experimental effort through profound chemical understanding, the application of in silico software tools and a systemic analysis approach.
RD&C is happy to announce that the proposed project "Solid phase reaction toolbox" was found eligible for funding by the Austrian Wirtschaftsservice within the "Innovative Services Call".
Current Step 2b version. We provide support to implement the changes of this global policy for limiting metal impurities qualitatively and quantitatively in drug products and ingredients.
Helmut Buschmann has been nominated Series Editor of Wiley VCH's book series "Methods and Principles in Medicinal Chemistry”